vimarsana.com
  1. Home
  2. Live Updates
  3. Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA : vimarsana.com

Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA

Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA

apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

California ,United States ,Texas ,Susan Perlman ,Andres Lorente ,Los Angeles ,Manmeet Soni ,University Of California ,Department Of Neurology ,David Geffen School Of Medicine ,European Commission ,Drug Administration ,Nasdaq ,Exchange Commission ,Reata Pharmaceuticals Inc ,Kyowa Kirin Co Ltd ,New Drug Application ,United States Food ,Warren Huff ,Chief Executive ,David Geffen School ,Orphan Drug ,Reata Pharmaceuticals ,Annual Report ,Business Wire ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.